Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)

Next Previous
X
Search
Trial Profile

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rhenium (186Re) obisbemeda (Primary)
  • Indications Astrocytoma; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Glioma
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms ReSPECT; ReSPECT-GBM; ReSPECT-TM
  • Sponsors Plus Therapeutics

    • Most Recent Events

    • 14 Aug 2024 According to a Plus Therapeutics media release, data from this study will be presented at the Congress of Neurological Surgeons (CNS) Annual Conference (September 28-October 2, 2024).
    • 12 Aug 2024 According to a Plus Therapeutics media release, this trial is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH).
    • 02 Jul 2024 According to a Plus Therapeutics media release, the company announced that data from this study will be presented at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer on July 8, 2024 in Newry, Maine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top